Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Alimera Sciences Inc (ALIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,998
  • Shares Outstanding, K 71,000
  • Annual Sales, $ 46,970 K
  • Annual Income, $ -16,380 K
  • 60-Month Beta 2.14
  • Price/Sales 1.34
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.11
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/23/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.85 +7.05%
on 04/22/19
1.02 -10.79%
on 04/29/19
-0.05 (-5.09%)
since 04/17/19
3-Month
0.85 +7.05%
on 04/22/19
1.21 -24.80%
on 03/06/19
-0.17 (-15.75%)
since 02/15/19
52-Week
0.72 +26.73%
on 12/31/18
1.21 -24.80%
on 03/06/19
+0.13 (+16.65%)
since 05/17/18

Most Recent Stories

More News
Alimera Sciences to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that President and CEO, Rick Eiswirth will present...

ALIM : 0.91 (+2.55%)
Global Ocular Inflammation Treatment Market Size, Status and Forecast 2019-2025

Eye inflammations or uveitis are becoming a common problem for people across global geographies. New drugs are being discovered to treat ocular inflammations, and companies are investing millions for their...

VRX.TO : 30.80 (-3.33%)
ALIM : 0.91 (+2.55%)
AGN : 140.20 (+0.11%)
NVS : 82.70 (+0.30%)
AKRX : 4.19 (-1.87%)
PFE : 41.47 (-0.41%)
Alimera Sciences Announces First Quarter 2019 Financial Results and Provides Corporate Overview

First Quarter and Recent Company Highlights:

ALIM : 0.91 (+2.55%)
Alimera Sciences to Report First Quarter Financial Results on Monday, April 29, 2019 and Provide Corporate Update

ALIM : 0.91 (+2.55%)
Alimera Sciences Announces Multiple Posters and a Podium Presentation of Clinical Data for ILUVIEN(R) to be Presented at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting

ATLANTA, GA / ACCESSWIRE / April 23, 2019 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that...

ALIM : 0.91 (+2.55%)
Ocular Inflammation Treatment Market to Grow US$ 500 Billion by 2024

New York, April 08, 2019: The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

VRX.TO : 30.80 (-3.33%)
ALIM : 0.91 (+2.55%)
AGN : 140.20 (+0.11%)
NVS : 82.70 (+0.30%)
AKRX : 4.19 (-1.87%)
PFE : 41.47 (-0.41%)
Alimera Sciences Announces Expansion of Leadership Team with Appointment of Samer Kaba, MD as Chief Medical Officer

ATLANTA, GA / ACCESSWIRE / April 4, 2019 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced...

ALIM : 0.91 (+2.55%)
2019 Global Ocular Inflammation Treatment Market Research Report with Industry Forecast 2025 and Outlook

The global Ocular Inflammation Treatment market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.This report focuses on Ocular...

VRX.TO : 30.80 (-3.33%)
ALIM : 0.91 (+2.55%)
AGN : 140.20 (+0.11%)
NVS : 82.70 (+0.30%)
AKRX : 4.19 (-1.87%)
PFE : 41.47 (-0.41%)
Alimera Sciences Announces Approval Received in the Mutual Recognition Procedure for New Indication for ILUVIEN(R) in Europe

ALIM : 0.91 (+2.55%)
Alimera Sciences Announces Approval for ILUVIEN (R) in Kuwait

Kuwait Added to the Growing Number of Countries with Approval for ILUVIEN in the Middle East

ALIM : 0.91 (+2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade ALIM with:

Business Summary

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes...

See More

Key Turning Points

2nd Resistance Point 0.96
1st Resistance Point 0.94
Last Price 0.91
1st Support Level 0.89
2nd Support Level 0.86

See More

52-Week High 1.21
Fibonacci 61.8% 1.02
Fibonacci 50% 0.96
Fibonacci 38.2% 0.91
Last Price 0.91
52-Week Low 0.72

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar